Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Final results of the INFINITY precision oncology registry: non-standard targeted treatments in patients with advanced cancers in routine care.

ESMO real world data and digital oncology·2026
Same author

Individualized mRNA vaccines evoke durable T cell immunity in adjuvant TNBC.

Nature·2026
Same author

Long-term effect of neoadjuvant denosumab treatment in high-risk early breast cancer (GeparX).

ESMO open·2025
Same author

Safety and efficacy of tiragolumab, atezolizumab and chemotherapy for early-stage or PD-L1-positive advanced triple-negative breast cancer: a phase Ib study.

ESMO open·2025
Same author

Evaluation of the practice of reprocessing ORs in German hospitals from an infection prevention and control perspective.

Infection·2024
Same author

Long-term outcomes of a randomized, open-label, phase II study comparing cabazitaxel versus paclitaxel as neoadjuvant treatment in patients with triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE).

ESMO open·2024
Same journal

ASO Author Reflections: Does the Axilla Still Matter? Rethinking Nodal Staging in the Era of CDK4/6 Inhibition.

Annals of surgical oncology·2026
Same journal

Omission of Axillary Surgery in Patients with Invasive Lobular Carcinoma of the Breast: Rates of Nodal Involvement in Clinically Node Negative Patients and Impact on Recurrence in a Single Institution Analysis.

Annals of surgical oncology·2026
Same journal

Is Mastectomy Necessary in Patients with Occult Breast Cancer and Advanced (N2/N3) Nodal Disease?

Annals of surgical oncology·2026
Same journal

Expanding Eligibility for Targeted Axillary Dissection.

Annals of surgical oncology·2026
Same journal

ASO Author Reflections: Reconsidering Surgical Indications for Clinical T4 Non-Small Cell Lung Cancer in the TNM 9th Edition Era.

Annals of surgical oncology·2026
Same journal

Potential Impact of Sentinel Lymph Node Biopsy Omission on Adjuvant Treatment Decisions in Low-Risk Breast Cancer: A Regional Multicenter 775 Patient Review of Current Practice in the United Kingdom.

Annals of surgical oncology·2026
See all related articles

Related Experiment Video

Updated: Mar 31, 2026

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence
08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

12.9K

Can Routine Imaging After Neoadjuvant Chemotherapy in Breast Cancer Predict Pathologic Complete Response?

B Schaefgen1, M Mati1, H P Sinn2

  • 1Department of Gynecology, University Breast Unit, Heidelberg, Germany.

Annals of Surgical Oncology
|October 16, 2015
PubMed
Summary
This summary is machine-generated.

Breast cancer imaging like MRI, mammography, and ultrasound cannot reliably predict pathologic complete response (pCR) after neoadjuvant chemotherapy (NACT) to replace surgical pathology. Further research is needed to improve diagnostic accuracy.

More Related Videos

Tissue-simulating Phantoms for Assessing Potential Near-infrared Fluorescence Imaging Applications in Breast Cancer Surgery
11:05

Tissue-simulating Phantoms for Assessing Potential Near-infrared Fluorescence Imaging Applications in Breast Cancer Surgery

Published on: September 19, 2014

12.8K
Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
07:32

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

Published on: April 12, 2024

2.1K

Related Experiment Videos

Last Updated: Mar 31, 2026

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence
08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

12.9K
Tissue-simulating Phantoms for Assessing Potential Near-infrared Fluorescence Imaging Applications in Breast Cancer Surgery
11:05

Tissue-simulating Phantoms for Assessing Potential Near-infrared Fluorescence Imaging Applications in Breast Cancer Surgery

Published on: September 19, 2014

12.8K
Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
07:32

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

Published on: April 12, 2024

2.1K

Area of Science:

  • Oncology
  • Radiology
  • Pathology

Background:

  • Neoadjuvant chemotherapy (NACT) is a standard breast cancer treatment.
  • Pathologic complete response (pCR) after NACT is a key indicator of treatment success.
  • Accurate prediction of pCR is crucial for treatment planning and patient management.

Purpose of the Study:

  • To evaluate the accuracy of breast imaging procedures in predicting pCR after NACT.
  • To compare the performance of MRI, mammography (MGR), and ultrasound (US) in assessing treatment response.
  • To determine if imaging can replace surgical pathology for pCR diagnosis.

Main Methods:

  • Retrospective, exploratory, monocenter study of 150 invasive breast cancers.
  • Patients underwent MRI, MGR, and US post-NACT.
  • Response categorized using RECIST criteria, with an added 'clinical near complete response' (near-cCR) for MRI/MGR. Analyzed Negative Predictive Values (NPVs), False Negative Rates (FNRs), and False Positive Rates (FPRs).

Main Results:

  • 31% of patients achieved pCR (ypT0).
  • MRI showed the highest NPV (61%) for near-cCR in the overall cohort; MGR had the lowest (44%).
  • MRI demonstrated superior performance in triple-negative (TN) cancers (NPV 94%, FNR 5%) with the lowest FPR (10%). US had the highest FPR (44%).

Conclusions:

  • Current imaging modalities (MRI, MGR, US) lack sufficient accuracy to replace surgical pathology for diagnosing pCR.
  • Pathologic assessment of the surgical specimen remains the gold standard for confirming pCR after NACT.
  • Further advancements in imaging techniques are needed to improve pCR prediction.